Free Trial

TriSalus Life Sciences (TLSI) Competitors

TriSalus Life Sciences logo
$4.87 -0.01 (-0.20%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$4.89 +0.02 (+0.41%)
As of 09/23/2025 05:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TLSI vs. IRMD, EMBC, TNDM, AXGN, SIBN, BVS, AVNS, ZIMV, KIDS, and TMCI

Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include iRadimed (IRMD), Embecta (EMBC), Tandem Diabetes Care (TNDM), AxoGen (AXGN), SiBone (SIBN), Bioventus (BVS), Avanos Medical (AVNS), ZimVie (ZIMV), OrthoPediatrics (KIDS), and Treace Medical Concepts (TMCI). These companies are all part of the "medical equipment" industry.

TriSalus Life Sciences vs. Its Competitors

iRadimed (NASDAQ:IRMD) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

iRadimed has higher revenue and earnings than TriSalus Life Sciences. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRadimed$73.24M12.43$19.23M$1.6244.18
TriSalus Life Sciences$35.99M6.75-$30.05M-$1.18-4.13

iRadimed has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500.

In the previous week, iRadimed had 3 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 7 mentions for iRadimed and 4 mentions for TriSalus Life Sciences. iRadimed's average media sentiment score of 1.02 beat TriSalus Life Sciences' score of 0.53 indicating that iRadimed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
iRadimed
5 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TriSalus Life Sciences
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

iRadimed currently has a consensus target price of $72.00, suggesting a potential upside of 0.60%. TriSalus Life Sciences has a consensus target price of $10.90, suggesting a potential upside of 123.82%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe TriSalus Life Sciences is more favorable than iRadimed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
TriSalus Life Sciences
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.29

iRadimed has a net margin of 26.61% compared to TriSalus Life Sciences' net margin of -86.61%. iRadimed's return on equity of 23.30% beat TriSalus Life Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
iRadimed26.61% 23.30% 20.62%
TriSalus Life Sciences -86.61%N/A -116.50%

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 36.8% of iRadimed shares are owned by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

iRadimed beats TriSalus Life Sciences on 13 of the 17 factors compared between the two stocks.

Get TriSalus Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TLSI vs. The Competition

MetricTriSalus Life SciencesMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$243.35M$10.70B$5.76B$10.50B
Dividend YieldN/A1.90%5.53%4.57%
P/E Ratio-4.1320.5975.9626.62
Price / Sales6.7538.02473.7891.77
Price / CashN/A24.5937.4661.85
Price / Book-5.873.4013.486.45
Net Income-$30.05M$212.47M$3.29B$271.57M
7 Day Performance1.46%0.14%1.83%2.61%
1 Month Performance-3.56%-2.71%4.00%7.28%
1 Year Performance20.25%-10.38%75.89%29.60%

TriSalus Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TLSI
TriSalus Life Sciences
2.9056 of 5 stars
$4.87
-0.2%
$10.90
+123.8%
+16.5%$243.35M$35.99M-4.13106News Coverage
IRMD
iRadimed
4.7809 of 5 stars
$71.46
-0.2%
$72.00
+0.8%
+45.8%$908.97M$73.24M44.11110Positive News
EMBC
Embecta
4.4418 of 5 stars
$15.08
flat
$19.00
+26.0%
-4.3%$882.03M$1.12B10.552,100Positive News
TNDM
Tandem Diabetes Care
4.2682 of 5 stars
$12.43
+2.8%
$22.44
+80.5%
-71.9%$839.90M$940.20M-4.022,650Positive News
AXGN
AxoGen
2.8779 of 5 stars
$16.73
+2.2%
$26.00
+55.4%
+23.8%$769.75M$187.34M-167.28450
SIBN
SiBone
3.7896 of 5 stars
$15.10
-0.3%
$23.67
+56.7%
-4.0%$651.43M$185.26M-26.96350Positive News
BVS
Bioventus
N/A$6.84
-4.6%
N/AN/A$565.53M$573.28M14.461,200
AVNS
Avanos Medical
1.8172 of 5 stars
$11.89
-3.1%
N/A-49.6%$551.72M$692.50M-1.182,227Positive News
ZIMV
ZimVie
1.1762 of 5 stars
$18.89
flat
$17.75
-6.0%
+18.3%$532.89M$449.75M-26.991,770Positive News
KIDS
OrthoPediatrics
4.4129 of 5 stars
$19.59
+0.2%
$34.14
+74.3%
-30.6%$491.12M$204.73M-10.94200
TMCI
Treace Medical Concepts
2.3468 of 5 stars
$7.07
-2.1%
$9.83
+39.1%
+28.5%$446.61M$209.36M-8.95250

Related Companies and Tools


This page (NASDAQ:TLSI) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners